Volume 94 Issue 24 | p. 13 | Concentrates
Issue Date: June 13, 2016

Ixaltis gets funds to repurpose drug

Department: Business
Keywords: start-ups, drug development, financing, urogenital diseases

Ixaltis, a start-up company focused on urogenital disorders, has raised $9 million in its first funding round. The French firm’s pipeline consists of three compounds licensed from Sanofi. The most advanced is litoxetine, a serotonin reuptake inhibitor and 5-HT3 receptor antagonist that Sanofi had studied as an antidepressant. Ixaltis will soon begin testing the compound in a Phase II trial for treating urinary incontinence. The company also received a $3.2 million loan under an academic-industrial . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society